Sepsis is a leading cause of mortality in neutropenic cancer patients. Early initiation of effective causative therapy as well as intensive adjunctive therapy is mandatory to improve outcome. We give recommendations for the management of adults with neutropenia and sepsis. The guidelines are written for clinicians involved in care of cancer patients and focus on pathophysiology, diagnosis and treatment of sepsis during neutropenia.
introduction
Patients with hematologic malignancies or solid tumors undergoing intensive cytotoxic chemotherapy causing longterm granulocytopenia are at high risk of infectious complications [1] . Sepsis is a frequent syndrome caused by serious infections in this patient population and remains a leading cause of nonrelapse mortality [2] . Therefore, optimization of diagnosis and management of sepsis could improve outcome of intensive cytotoxic therapies. These guidelines were written to provide guidance on diagnosis and management of sepsis in the neutropenic host. First, a panel of eight experts in the field of infectious diseases in Hematology and Oncology systematically searched Medline for English language publications up to June 2009 using the key term 'sepsis' and one of the following: 'neutropenia', bloodstream infection, pathophysiology, definition, epidemiology, incidence, risk factors, prognosis, treatment, antibiotic, antifungal, cardiovascular, pulmonary failure, ventilation, renal dysfunction, renal failure, dialysis, hemofiltration, nutrition, hyperglycemia, steroid, coagulation, growth factor, immunoglobulin and transfusion. Meeting abstracts were not included; however, references generated from published guidelines and reviews were also investigated. The consensus process was carried out as an e-mail and meeting based discussion group. In a second step, the panelists draft was peer reviewed by the review committee of the Infectious Diseases Working Party of the German Society of Hematology and Oncology on 2 October 2009. In a third step, the guideline was approved by the assembly of the members on 22 January 2010. Criteria used to quote levels and grades of evidence are as outlined in Table 1 [3] .
A number of prior guidelines on the management of sepsis have been published [4] [5] [6] [7] [8] [9] ; however, none of these guidelines specifically addresses diagnosis and management of sepsis in neutropenic patients.
pathophysiology
Sepsis is a systemic inflammatory response syndrome (SIRS) that is characterized by widespread tissue injury often due to severe infection. Pathogens or microbial associated molecules (pathogen-associated molecular patterns) cause tissue damage and inflammatory reactions. Organ dysfunction results from direct cytotoxic effects of inflammatory mediators and microbial toxins as well as from dysregulation of microcirculation and macrocirculation, oxygen transport and tissue oxygenation. Recruitment of inflammatory cells, endothelial damage and activation of endothelial cells leading to increased permeability of the vessel wall appear to be additional factors contributing to organ dysfunction [10, 11] . Interstitial edema, capillary microembolization or microthrombi and loss of regulation of the microvascular blood flow lead to perfusion mismatch with a decrease in peripheral vascular resistance. The decrease in vascular resistance is partially compensated by an increase in heart frequency but potentially reversible myocardial depression often prevents an adequate increase of cardiac output. This is thought to be caused by myocardial depressant factors, such as toxins, cytokines, metabolic defects of myocytes and down-regulation of beta-receptors (septic cardiomyopathy). Additional factors are a decrease in preload induced by a change in ventricular compliance and a decrease in right ventricular venous retour (venous pooling, volume deficiency by fluid sequestration). Another important pathophysiological factor is a decrease in tissue oxygenation. Besides a restriction of global oxygen transport (respiratory failure, decrease in cardiac output and anemia), inadequate regional oxygen supply due to perfusion mismatch is possibly a critical factor [12] .
definition
A formal definition of sepsis has long been tried by several researchers and must lack specificity given the broad spectrum of reactions to pathogens. The definition of sepsis suggested by the consensus conference of the American College of Chest Physicians and the Society of Critical Care Medicine (ACCP/ SCCM) in 1992 [13] Current concepts of sepsis, severe sepsis and septic shock remain useful to clinicians and researchers.
These definitions do not allow precise staging or prognostication of the host response to infection. While SIRS remains a useful concept, the diagnostic criteria for SIRS published in 1992 are overly sensitive and nonspecific. An expanded list of signs and symptoms of sepsis may better reflect the clinical response to infection (Table 2) [14, 15] .
We suggest to use the diagnostic criteria for sepsis proposed by the SCCM, ESICM, ACCP, ATS and SIS adapted to neutropenic patients (Table 2) [14, 15] . In neutropenic patients, the white blood cell count (numbers of leukocytes) cannot be used as criterion to define sepsis.
The definitions of severe sepsis and septic shock remain unchanged and refer to sepsis-induced organ dysfunction ( Table 3) .
incidence
Prospective studies using the SCCM/ESICM/ACCP/ATS/SIS consensus definition in neutropenic patients are not available [14, 15] . However, it can be assumed that in >90% of febrile neutropenic episodes sepsis may be diagnosed using the consensus definition according to SCCM/ESICM/ACCP/ATS/ Arterial hypotension (systolic blood pressure < 90 mmHg, mean arterial pressure < 70 or a systolic blood pressure decrease > 40 mmHg in adults or < 2 SD below normal for age) Mixed venous oxygen saturation > 70% Cardiac index > 3.5 l/min/m 2 Organ dysfunction parameters Arterial hypoxemia (PaO 2 /FIO 2 < 300) Acute oliguria (urine output < 0.5 ml/kg/h or 45 mM/l for at least 2 h) Creatinine increase ‡ 0.5 mg/dl Coagulation abnormalities (international normalized ratio > 1.5 or activated partial thromboplastin time > 60 s) Ileus (absent bowel sounds) Thrombocytopenia (platelet count < 100 000/ll) Hyperbilirubinemia (plasma total bilirubin > 4 mg/dl or 70 mmol/l) Tissue perfusion parameters Hyperlactatemia (>3 mmol/l) Decreased capillary refill or mottling
In neutropenic patients the white blood cell count (numbers of leukocytes) cannot be used as criterion to define sepsis. SD, standard deviation.
SIS [14, 15] . The incidence of febrile episodes and consequently of sepsis during the neutropenic phase after intensive myelosuppressive chemotherapy lies 70%-100% [16] [17] [18] and depends on the intensity of chemotherapy and the degree and duration of neutropenia as well as the overall performance status and pretreatment of the patient. In the majority of studies, bacteremic infections could be detected in 10%-30% of febrile neutropenic episodes [2, 19] . The incidence of septic shock and severe sepsis has not been reported from the majority of trials but in some studies, 40% of the patients treated with intensive chemotherapy developed severe sepsis or septic shock. As in the general population, an overall increase in number and severity of septic episodes can be assumed [17] .
risk factors and prognosis
Main risk factors following cytotoxic chemotherapy are the severity and duration of granulocytopenia [1, 19] . In addition, skin and mucosal barriers can be disrupted by chemotherapy, insertion of catheters (staphylococci and fungi) and invasive diagnostic procedures or by invasive tumor growth (colon cancer) [2] . Decreased production of saliva or retention of secretion due to tumor obstruction (particularly in patients with lung cancer) facilitates the growth of pathogenic microorganisms. Furthermore, the incidence of infection is increased in malnourished tumor patients. In 2000, the Multinational Association for Supportive Care in Cancer (MASCC) proposed a score to identify febrile neutropenic patients at low risk [20] . In addition to providing a useful tool to aid the decision whether to admit a febrile patient, a recent study has also identified the MASCC risk score as an independent prognostic factor to predict complications during the febrile episode [21] . The presence and degree of multiple organ dysfunction and development of septic shock defined by volume-refractory hypotension are prognostic factors [22] . The criteria of leukocytosis, leukocytopenia or shift to the left in the differential white blood cell count cannot be used in patients with sepsis in neutropenia. Any neutropenic patient with signs of a systemic inflammatory reaction without an obvious cause other than infection (like blood transfusion or high-dose cytarabine) has a high probability of sepsis. Thus, the use of the consensus criteria [14] is also recommended for leukocytopenic/neutropenic patients as no specific criteria for this patient group have been specified as yet.
The prognosis of patients treated on the intensive care unit (ICU) is determined by the physiological changes induced by the underlying infection, reflected by scoring systems such as Acute Physiology and Chronic Health Evaluation II (APACHE II) and Simplified Acute Physiology Score II (SAPS II). However, long-term prognosis of these patients often depends on the underlying malignant disease, rendering the SAPS II score in leukocytopenic/neutropenic patients less useful than in nonneutropenic patients (CII) [23] . With regard to scores predicting outcome in respiratory failure requiring ventilatory support a high APACHE II score was significantly correlated with high in-ICU mortality but not with long-term outcome [24] . In a retrospective study, a high SOFA score at ICU admission, pulmonary site of infection and fungal infection were variables independently associated with a higher 28-day mortality [25] . In general, it has to be kept in mind that prognostic scoring systems do not yield adequately reliable information to be used exclusively for end-of-life decisions in individual patients [26] . Increased levels of proinflammatory [tumor necrosis factor (TNF)-a, nterleukin (IL)-6 and IL-8] as well as anti-inflammatory cytokines (IL-10, IL-1RA) are found in neutropenic and nonneutropenic patients with sepsis [27] . This is also the case for procalcitonin levels, which can be useful in the early diagnostic phase before rise of C-reactive protein in serum [28, 29] .
Septic shock and multiple organ failure syndrome are often associated with systemic activation of coagulation and fibrinolysis, disseminated fibrin deposition and consumption of coagulation and fibrinolysis inhibitors. Disturbances of hemostasis are of prognostic relevance in sepsis. For antithrombin and PAI 1, prognostic relevance in neutropenic sepsis could be shown [30] .
microbiology
Blood cultures as part of the usual microbiological work-up as per local protocol (including for instance urine cultures, stool cultures etc.) remain the gold standard for the diagnosis of bacteremia. Detailed recommendations regarding the application of microbiological tests in this situation are given elsewhere [31] [32] [33] . However, although most episodes of febrile neutropenia are assumed to be caused by an infection, the incidence of proven bloodstream infections in febrile neutropenia is only 30% based on results of blood cultures [34, 35] . Recent studies reporting a higher yield of positive results by various PCR-based methods to detect bacterial and fungal DNA have yet to be validated in larger cohorts [36, 37] . Particularly in the detection of bacteria at the beginning of febrile neutropenia, PCR-based methods may add little further information compared with blood cultures [38] . In contrast, PCR-based methods play a definitive role in the diagnosis of specific pathogens like combination chemotherapy with methotrexate, vinblastine and cisplatin (CMV), which can be the cause of neutropenic fever regardless of prior allogeneic stem cell transplantation requiring early detection and treatment [39] .
treatment antimicrobial treatment
Empirical antimicrobial treatment using broad-spectrum antibiotics must be started immediately in neutropenic patients with sepsis. A large retrospective study including >2000 patients showed that during severe sepsis effective antimicrobial administration within the first hour of documented hypotension is associated with increased survival [40] . In this study, each hour of delay in antimicrobial administration over the ensuing 6 h was associated with an average decrease in survival of 7.6% [40] .
Recommendations on antimicrobial treatment of infections during neutropenia are given elsewhere [31, 32, 41] . Briefly, we recommend initial treatment with meropenem or with imipenem/cilastin or with piperacillin/tazobactam monotherapy. Treatment with ceftazidim is an alternative option. A combination treatment with an aminoglycoside has not improved efficacy but increased renal toxicity [42, 43] . However, in case of severe sepsis, a combination treatment with aminoglycoside is carried out in many centers and is recommended by the European Organization for Research and Treatment of Cancer infectious disease group. If infection due to bacteria with frequent resistance to carbapenem or piperacillin/tazobactam is suspected, a specific antibiotic should be added (e.g. a glycopeptide in sepsis suspected to be central venous catheter related). Recommendations on antifungal therapy during neutropenia were recently published by the infectious disease working party of the German Society for Hematology and Oncology [44] . Knowledge of local microbiology data is crucial for the choice of antimicrobial agents. Typical organisms causing sepsis during neutropenia are summarized in Table 4 .
treatment of cardiovascular insufficiency
Aggressive and early goal-directed treatment aiming at restoration of cardiovascular function has the potential to increase survival of patients with sepsis if it is successful within the first 6 h [45, 46] . Sepsis-induced hypotension or lactic acidosis in patients at risk is primarily treated by volume substitution. To restore adequate cardiac filling pressures and to maintain adequate organ perfusion (goal: mean arterial pressure ‡ 65 mmHg, central venous pressure 8-12 mmHg, pulmonary wedge pressure 12-15 mmHg, urinary output ‡ 0.5 ml/kg/h and central venous or mixed venous oxygen saturation ‡ 70%), crystalloid fluids or colloids can be useful (AI) [46, 47] .
Resuscitation with crystalloids requires more fluid volume because of the larger volume of distribution. However, there is no evidence-based support for the preferred use of colloids over crystalloids. A meta-analysis and a large multicenter trial revealed a small absolute increase in the risk of renal failure and mortality with the use of colloids over crystalloids [46, 47] . Human albumin should not be used because in meta-analyses of randomized trials, the application of human albumin was not associated with a favorable outcome even if administered in patients with burns and hypoalbuminemia (DII) [48] . Treatment with volume substitution should be done under hemodynamic monitoring (central venous pressure, blood pressure, heart rate, cardiac output, pulmonary wedge pressure and lactate levels). If a sufficient mean arterial pressure (>65 mmHg) cannot be achieved by volume substitution in a reasonable time frame, treatment with vasopressors is indicated. The drug of choice to elevate the vasotonus is norepinephrine in a dose of 0.1-1.3 lg/ kg/min (BII) [49] . This may also lead to an improvement in renal function [50] . There is no evidence that increasing the mean arterial pressure to >85 mmHg by using high doses of vasopressors, such as norepinephrine, has a positive impact on oxygen delivery and renal function (EI) [51] . Another vasopressor that has been investigated in smaller studies is vasopressin. Vasopressin (0.01-0.04 U/min) increased urinary output and creatinine clearance in comparison to norepinephrine [52] [53] [54] . However, in the large VASST trial, no reduction in 28-day mortality was found in the vasopressin group and there is currently poor evidence to support the use of vasopressin in septic shock (CI) [55] .
In case of sepsis-related myocardial depression leading to low cardiac output despite adequate volume substitution, vasopressor treatment with dobutamine should be instituted (AII) [56] . Because of their toxicity profile and due to lack of evidence of a beneficial effect, epinephrine and dopamine are not recommended.
Bicarbonate therapy is not recommended for the purpose of improving hemodynamics or reducing vasopressor requirements in the presence of lactic acidosis and pH >7.15.
treatment of pulmonary failure
Nearly 15% of cancer patients experience acute respiratory failure requiring admission to the ICU, where their mortality is 50% [57] . Nearly 50% of patients with severe sepsis will develop acute lung injury/acute respiratory distress syndrome (ARDS) [58] .
In the awake, cooperative patient with a minor disturbance of gas exchange (PaO 2 /FiO 2 > 200), an augmentation of spontaneous breathing with intermittent continuous positive airway pressure (CPAP) can be attempted. In moderate-tosevere respiratory insufficiency, endotracheal intubation and controlled mechanical ventilation are necessary. However, noninvasive positive pressure ventilation (CPAP or bilevel positive airway pressure) should be preferred if possible in patients without hypotension or altered mental status [58] [59] [60] [61] . Both noninvasive treatment options led to a significant reduction of intubation compared with the control group in selected neutropenic and cancer patients (AII) [62] . An early start of noninvasive ventilation, before development of severe hypoxemia, is favorable (BIII), and predictors of noninvasive ventilation failure might be used to guide decisions regarding intubation. These include respiratory rate under noninvasive ventilation (longer), delay between admission and noninvasive ventilation first use [63] , need for vasopressors or renal replacement therapy (RRT) and the development of ARDS [64] . Failure of noninvasive ventilation occurs in half the critically ill hematologic patients and is associated with an increased mortality [63] . In a retrospective multicenter study of allogeneic hematopoietic stem cell transplantation recipients admitted to the ICU, mechanical ventilation led to a dramatic decrease in survival rates [41] .
Regarding diagnostic procedures in the work-up of lung infiltrates, fiberoptic bronchoscopy with bronchoalveolar lavage (FO-BAL) is considered a cornerstone of the causal diagnosis [41] . The diagnostic yield of at most 50% is related to the widespread use of broad-spectrum antimicrobial therapy in these patients [65, 66] . However, in patients with hypoxemia, bronchoscopy and BAL may trigger a need for invasive mechanical ventilation, thus considerably decreasing the chances of survival [57, 67] . Respiratory status deterioration after FO-BAL occurred in up to 50% of nonintubated patients, including 35.5% patients who required ventilatory support [67] . Life-threatening complications were noticed in up to 10% of FO-BAL procedures [66] .
In patients with pulmonary infiltrates during neutropenia, granulocyte colony-stimulating factor (G-CSF)-induced neutropenia recovery carries a risk of respiratory status deterioration with acute lung injury or ARDS [68] .
management of renal dysfunction
Acute renal failure (ARNF) develops in 23% of patients with severe sepsis and 51% with septic shock. The combination of ARNF and sepsis is associated with a 70% mortality [69] . The pathophysiology of septic ARNF remains incompletely understood but renal hypoperfusion and ischemia followed by acute tubular necrosis are considered to be central. Hyperemia, vasodilatation and nonhemodynamic mechanisms may also play a role in the pathogenesis of septic ARNF [70] .
ARNF in patients with sepsis necessitates the replacement of renal function to balance fluids, remove uremic toxins and control electrolytes. Currently, no clear guidelines on the timing of the initiation of RRT can be given, and decisions should be made on an individual basis [71] . The only randomized trial, carried out in mainly surgical patients with ARNF, did not show a benefit for the early initiation of hemofiltration [72] . However, given the increased risk of severe extrarenal complications, the initiation of RRT should not be delayed in patients with rapidly developing oliguric forms of ARNF (BIII) [71] .
Regarding the mode of replacement therapy intermittent hemodialysis (IHD) and continuous renal replacement therapies (CRRT) are equivalent in patients with sepsis and ARNF (BI). Three meta-analyses did not show a significant difference in hospital mortality between patients who receive intermittent or continuous RRT [73] [74] [75] . Moreover, two additional randomized controlled trials, which were not included in the meta-analyses, also found intermittent or CRRT equally effective with similar rates of survival [76, 77] . In hemodynamically unstable patients, control of fluid balance may be facilitated by the use of CRRT (BII) [45, 71] , although there is no strong evidence for a better hemodynamic tolerance with continuous therapies as compared with IHD. In terms of hemodynamic stability four of six prospective randomized studies did not show a significant difference between either method [45, 71] .
Increasing the dose of RRT is thought to reduce the rate of uremic complications and improve outcome in patients with ARNF. However, randomized controlled studies showed conflicting results [45, 71, 78] . A recent study indicates that a strategy of intensive renal support in critically ill patients with ARNF does not decrease mortality, accelerate recovery of kidney function or alter the rate of nonrenal organ failure as compared with less-intensive regimens [79] . Thus, no firm recommendations can be given for the use of increased doses of RRT (CI).
In patients undergoing RRT, the dosage of antimicrobial substances should be carefully checked and adjusted. The use of low-dose dopamine for protection of renal function is not recommended (EI) [80, 81] .
nutrition and control of metabolic functions
An oral diet is preferred over parenteral nutrition unless contraindicated or impossible, e.g. due to mucositis induced by chemotherapy and radiation. Enteral caloric intake should be calculated according to the phase of sepsis: during the initial phase of sepsis, the supply of >20-25 kcal/kg ideal body weight (IBW) has been associated with inferior outcome in one observational study (DIII) [82] . During recovery, 25-30 kcal/kg IBW should be provided (BIII) [83, 84] . Peptide-based formulae are not superior to whole protein formulae [83, 84] .
Patients with mild sepsis (APACHE II 10-15) might benefit from receiving a formulation enriched with arginine, nucleotides and x -3-fatty acids (BI) [83, 85] . In one randomized controlled trial, mortality of these patients was reduced, whereas the mortality of patients with an APACHE II score of 16-25 was not affected [85] . This formulation is also superior to standard enteral formulae in patients with ARDS, with burns or with trauma. In contrast, the formulation is discouraged in patients with severe sepsis and an APACHE II score of >25 because their mortality may be increased (EII) [85] .
Hyperglycemia in patients requiring intensive care is associated with inferior outcome [86, 87] , Yet, results of recently published clinical trials [88] [89] [90] do not support aiming at a strictly normal blood glucose level of 4.4-6.6 mmol/l (80-120 mg/dl) (EI). Two randomized controlled trials, one including patients with severe sepsis [89] and the other including both medical and surgical patients requiring treatment on an ICU [90] , had failed to repeat the results of the initial trials by van den Berghe et al. [91, 92] suggesting a benefit of a tight blood glucose control. Mortality, the rates of severe hypoglycemia and serious adverse events were increased in patients subjected to intensified blood glucose control [89, 90] . In a meta-analysis including 26 trials, the pooled relative risk (RR) of death with intensive insulin therapy when compared with conventional insulin therapy was 0.93 [95% confidence interval (CI) 0.93-1.04] [88] . The pooled RR for hypoglycemia with intensive insulin therapy was 6.0 (95% CI 4.5-8.0). In addition, a recently published trial showed that intensive insulin therapy did not improve in hospital mortality, compared with conventional insulin therapy, among patients who were treated with hydrocortisone for septic shock [93] . Based on these data, we recommend to maintain blood glucose levels £8.3 mmol/l (150 mg/dl) in septic patients (BIII). We do not recommend, however, intensive insulin therapy aiming at a strictly normal blood glucose level of 4.4-6.6 mmol/l (80-120 mg/dl) (EI).
Selenium exerts antioxidative effects. It has been proposed that the substitution of selenium might positively influence the outcome of patients suffering from sepsis. The per protocol analysis of one small, randomized, placebo controlled clinical trial [94] showed a reduction in the 28-day mortality rate by the administration of high-dose selenium (1000 lg daily over 15 days, 42.4% in the treatment arm of the trial compared with 56.7% in the placebo group, P = 0.049, odds ratio, 0.56; 95% CI 0.32-1.00). Further clinical trials are needed before treatment with selenium can be recommended (CI).
Replacement of an impaired adrenal reserve and antiinflammatory properties has been the rationale for studying corticosteroids as an adjunctive to sepsis therapy. The use of corticosteroids in sepsis has not been studied in a prospective fashion in neutropenic patients. Meta-analyses reported on increased overall mortality and increased mortality from secondary infections in nonneutropenic patients with sepsis receiving high-dose steroids [95, 96] . Thus, high-dose corticosteroids should not be used in neutropenic or nonneutropenic septic patients (EI). However, in patients requiring corticosteroids or mineralocorticoids for treatment of diseases other than sepsis (e.g. graft versus host disease), steroid treatment should not be discontinued.
Interestingly, low doses of hydrocortisone might enhance immune responses [97, 98] . Substitutive doses of hydrocortisone during sepsis remain controversial [99] [100] [101] as two recent meta-analyses support the use of low doses of hydrocortisone [102, 103] but the CORTICUS trial [99] did not reveal a difference in 28-day mortality between treatment and placebo. A higher incidence of secondary infections was recorded in the treatment group. Thus, we do not recommend the use of substitutive doses of hydrocortisone in neutropenic patients with sepsis (DI).
treatment with coagulation inhibitors
Disseminated activation of the coagulation cascade is an early event, resulting in fibrin deposition in the microcirculation thus contributing to multiorgan dysfunction in sepsis. Various attempts have been made to reverse or avoid disseminated coagulation. However, since neutropenia is usually accompanied by thrombocytopenia, any manipulation of the coagulation system has to be exerted with caution to avoid an excessive risk of bleeding.
The prospective, randomized controlled HETRASE study investigated treatment with low-dose heparin (500 IU/h for 7 days) in 319 patients [104] . No influence on 28-day all-cause mortality was found [104] . Inclusion criteria were very liberal, explaining the low mortality in this trial, and treatment was discontinued immediately in case the partial thromboplastin time rose >60 s. Under these conditions, the administration of low-dose heparin was safe. Further trials including more patients and better-defined subgroups, e.g. on the base of the APACHE II score, are needed before recommendations can be made (CI).
Antithrombin III (ATIII) exerts antithrombotic and antiinflammatory properties. The negative data from the KyberSept trial [105] have recently been confirmed by a Cochrane analysis [106] . Subgroup analyses have shown that concomitant administration of heparin impairs beneficial effects of antithrombin, especially in patients with disseminated intravascular coagulation [107] [108] [109] . No evidence-based recommendation on the use of ATIII in severe sepsis can be made (CI).
In patients without thrombocytopenia, the use of recombinant human activated protein C (APC) is recommended in patients with severe sepsis and septic shock who have an APACHE II score of >25 or a minimum of two organs failing (AI) [110] . It is not recommended in patients with an APACHE II score of <25 or one organ failure (EI) [111] . The PROWESS trial was prematurely stopped because a reduction in absolute mortality at day 28 by 6% was achieved [110] . Subgroup analyses of the PROWESS trial and the following ADDRESS trial did not manage to prove a benefit for lower risk groups (i.e. with an APACHE II score <25 or one organ failure) but increased the risk of bleeding [111] . Because APC increases the risk of bleeding, it is not recommended if thrombocytopenia <30 000 platelets/ll is present and within 30 days after larger surgery or spinal puncture/anesthesia. It is feasible to administer APC together with heparin [112] . The PROWESS trial [110] reported antagonizing interactions between the respective intervention and low-dose heparin. Those were not found in the XPRESS trial [113] . At present, no recommendation on the concomitant use of APC and low-dose heparin can be made.
cytokines and hematopoietic growth factors (G-CSF and granulocyte-macrophage colonystimulating factor)
The central role of cytokines during the hyperinflammatory and anti-inflammatory phases of sepsis prompted clinical studies on the use of cytokines and cytokine inhibitors as therapeutic agents. However, studies on the therapeutic efficacy of IL-1 receptor antagonist, TNF inhibitors and interferon gamma did not show a clinical benefit (EI) [114] [115] [116] .
The known effect of G-CSF and granulocyte-macrophage colony-stimulating factor (GM-CSF) in increasing the number of circulating neutrophil granulocytes was the rationale for clinical studies assessing their role as additional therapy to antibiotics in febrile patients with chemotherapy-induced neutropenia. A meta-analysis of 13 randomized controlled trials including a total of 1518 individuals showed that CSF effectively reduces the time to neutrophil recovery and the length of hospitalization [117] . However, despite a marginally significant benefit for the use of CSF in reducing infection-related mortality, overall mortality appeared not to be influenced. Even though studies enrolled in this meta-analysis report only mild side-effects associated with CSF treatment (bone pain, joint pain and flu-like symptoms), there is an accumulating number of studies reporting respiratory deterioration with ARDS during CSF-induced neutropenia recovery [68, 118] . In nonneutropenic patients with pneumonia or sepsis CSF appeared to be safe but ineffective in reducing mortality rates or complications from infection [119, 120] . On the basis of the current studies and reports, the Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie (AGIHO) does not recommend the routine additional use of G-CSF or GM-CSF to standard treatment of sepsis in neutropenia (DI).
immunoglobulins
The treatment of sepsis in neutropenia with i.v. immunoglobulin's (i.v. Ig) did not show a significant difference in survival in a randomized controlled trial [121] . A metaanalysis on trials of i.v. Ig in patients with sepsis identified 20 The cut-off for substitution of platelets is often set to a higher value (platelets 20 000/ll instead of 10 000/ll) during sepsis trials eligible for evaluation [122] . Compared with placebo or no intervention, the use of polyclonal i.v. Ig was associated with a survival benefit (RR 0.74 with a 95% CI 0.62-0.84). The number needed to treat to save one life was 9. Interestingly, more severely ill patients, those receiving treatment of >2 days and those receiving at least 1 g/kg, seemed to benefit most. As most of the individual trials analyzed had flaws in design, were rather small or carried out during a time when the standard of care for septic patients was different from today, the authors conclude that a large, randomized controlled trial should be carried out [122] . Two additional meta-analyses investigated the use of i.v. Ig during sepsis and had similar outcomes [123, 124] . In conclusion, there is moderate degree of evidence to support the use of i.v. Ig in sepsis (BII).
granulocyte transfusions
Several case reports and phase I/II studies have shown some efficacy of granulocyte transfusions in patients with infections during severe neutropenia including patients with invasive fungal infections. However, complications have been reported as well, e.g. fatal CMV infection, allo-immunization and the transfusion-related acute lung injury (TRALI) syndrome. Recently, a randomized controlled trial has been published [125] . It failed to show any beneficial effect, but it was small and the authors discussed several problems associated with the design of the trial. Therefore, no recommendation can be given on the use of granulocyte transfusions outside of clinical trials.
transfusion management in sepsis
The recommendations for substituting platelets or packed red blood cell in neutropenic patients can be applied to those patients developing sepsis as well. However, the cut-off for substitution is often set to a higher value (platelets 20 000/ll instead of 10 000/ll) (BIII). Although there are no prospective randomized studies showing a clinical benefit, hemoglobin levels should be kept >9 g/dl to optimize tissue oxygenation (BIII).
conclusions
Early start of effective antimicrobial treatment as well as intensive adjunctive therapy is mandatory to improve outcome of neutropenic patients with sepsis. 
